Autores: Salterain González, Nahikari (Autor de correspondencia)
; Rabago Juan Aracil, Gregorio
; Gómez-Bueno, M.; Almenar-Bonet, L.; Crespo-Leiro, M. G.; Arizón del Prado, J. M.; García-Cosío, M. D.; Martínez-Selles, M.; Mirabet-Pérez, S.; Sobrino-Márquez, J. M.; González-Costello, J.; Pérez-Villa, F.; Díaz-Molina, B.; De La Fuente-Galán, L.; Blasco-Peiró, T.; Garrido-Bravo, I. P.; García-Guereta Silva, L.; Gil-Villanueva, N.; Gran, F.; González-Vílchez, F.
Introduction and objectives: Heart retransplantation (ReHT) is controversial in the current era. The aim of this study was to describe and analyze the results of ReHT in Spain.
Methods: We performed a retrospective cohort analysis from the Spanish Heart Transplant Registry from 1984 to 2018. Data were collected on donors, recipients, surgical procedure characteristics, immunosuppression, and survival. The main outcome was posttransplant all-cause mortality or need for ReHT. We studied differences in survival according to indication for ReHT, the time interval between transplants and era of ReHT.
Results: A total of 7592 heart transplants (HT) and 173 (2.3%) ReHT were studied (median age, 52.0 and 55.0 years, respectively). Cardiac allograft vasculopathy was the most frequent indication for ReHT (42.2%) and 59 patients (80.8%) received ReHT > 5 years after the initial transplant. Acute rejection and primary graft failure decreased as indications over the study period. Renal dysfunction, hypertension, need for mechanical ventilation or intra-aortic balloon pump and longer cold ischemia time were more frequent in ReHT. Median follow-up for ReHT was 5.8 years. ReHT had worse survival than HT (weighted HR, 1.43; 95%CI, 1.17-1.44; P < .001). The indication of acute rejection (HR, 2.49; 95%CI, 1.45-4.27; P < .001) was related to the worst outcome. ReHT beyond 5 years after initial HT portended similar results as primary HT (weighted HR, 1.14; 95%CI, 0.86-1.50; P < .001).
Conclusions: ReHT was associated with higher mortality than HT, especially when indicated for acute rejection. ReHT beyond 5 years had a similar prognosis to primary HT.